tailieunhanh - Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness

Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared to ipilimumab is still ongoing, adoption of TIL therapy by the field is confronted with uncertainty. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN